Literature DB >> 16869776

Is oncogene addiction angiogenesis-dependent?

J Folkman1, S Ryeom.   

Abstract

Does an activated oncogene that initiates tumor growth need to remain activated to maintain the cancer phenotype? This question has been answered affirmatively by experiments in which doxycycline-regulated oncogene activation induces growth of large tumors that regress completely upon oncogene inactivation--a phenomenon called oncogene addiction. We assemble here the evidence that oncogene addiction is angiogenesis-dependent. Although activated oncogenes increase tumor cell proliferation and decrease their apoptosis, these activities are not sufficient to expand tumor mass beyond a microscopic size. Oncogenes must also induce tumor angiogenesis for expansion of tumor mass. We propose experiments to validate the "endothelial centric" hypothesis of oncogene addiction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869776     DOI: 10.1101/sqb.2005.70.042

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  8 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

2.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

3.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

4.  Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

Authors:  Alexander Zaslavsky; Kwan-Hyuck Baek; Ryan C Lynch; Sarah Short; Jenny Grillo; Judah Folkman; Joseph E Italiano; Sandra Ryeom
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

5.  C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling.

Authors:  Xian Lin; Ran Sun; Xiulan Zhao; Dongwang Zhu; Xueming Zhao; Qiang Gu; Xueyi Dong; Danfang Zhang; Yanhui Zhang; Yanlei Li; Baocun Sun
Journal:  J Mol Med (Berl)       Date:  2016-08-19       Impact factor: 4.599

6.  Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.

Authors:  J De Castro; J L González-Larriba; S Vázquez; B Massutí; J M Sanchez-Torres; M Dómine; P Garrido; A Calles; A Artal; R Collado; R García; M Sereno; M Majem; J A Macías; O Juan; J Gómez-Codina; B Hernández; M Lázaro; A L Ortega; M Cobo; J M Trigo; E Carcereny; C Rolfo; S Macia; J Muñoz; P Diz; M Méndez; F Rosillo; L Paz-Ares; J V Cardona; D Isla
Journal:  Clin Transl Oncol       Date:  2016-07-01       Impact factor: 3.405

7.  Cellular dormancy in minimal residual disease following targeted therapy.

Authors:  Jason R Ruth; Dhruv K Pant; Tien-Chi Pan; Hans E Seidel; Sanjeethan C Baksh; Blaine A Keister; Rita Singh; Christopher J Sterner; Suzanne J Bakewell; Susan E Moody; George K Belka; Lewis A Chodosh
Journal:  Breast Cancer Res       Date:  2021-06-04       Impact factor: 8.408

8.  Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer.

Authors:  Sophie Deharvengt; Melina Marmarelis; Murray Korc
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.